Inspire Medical Systems, Inc. (NYSE:INSP) Receives Consensus Rating of “Hold” from Brokerages

Inspire Medical Systems, Inc. (NYSE:INSP) has been assigned a consensus rating of “Hold” from the twenty ratings firms that are presently covering the firm, MarketBeat.com reports. Three investment analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and four have issued a buy rating on the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $81.8421.

INSP has been the subject of several research reports. UBS Group set a $67.00 price target on Inspire Medical Systems in a research note on Friday, February 13th. Stifel Nicolaus cut their price target on Inspire Medical Systems from $70.00 to $65.00 and set a “buy” rating for the company in a research note on Tuesday, May 5th. Piper Sandler downgraded Inspire Medical Systems from an “overweight” rating to a “neutral” rating and cut their price target for the stock from $85.00 to $55.00 in a research note on Tuesday, May 5th. Wolfe Research downgraded Inspire Medical Systems from an “outperform” rating to a “peer perform” rating in a research note on Friday, February 13th. Finally, Summit Redstone set a $39.00 price target on Inspire Medical Systems in a research note on Friday, May 22nd.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in INSP. Royal Bank of Canada boosted its stake in Inspire Medical Systems by 16.0% in the 1st quarter. Royal Bank of Canada now owns 32,769 shares of the company’s stock worth $5,220,000 after purchasing an additional 4,528 shares during the period. Integrated Wealth Concepts LLC bought a new position in Inspire Medical Systems in the 1st quarter worth about $524,000. Goldman Sachs Group Inc. boosted its stake in Inspire Medical Systems by 57.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 51,422 shares of the company’s stock worth $8,190,000 after purchasing an additional 18,857 shares during the period. Marshall Wace LLP boosted its stake in Inspire Medical Systems by 3.8% in the 2nd quarter. Marshall Wace LLP now owns 15,905 shares of the company’s stock worth $2,064,000 after purchasing an additional 577 shares during the period. Finally, Jump Financial LLC bought a new position in Inspire Medical Systems in the 2nd quarter worth about $931,000. Institutional investors own 94.91% of the company’s stock.

Inspire Medical Systems Stock Performance

INSP stock opened at $42.04 on Friday. The company has a market capitalization of $1.21 billion, a price-to-earnings ratio of 9.36, a PEG ratio of 4.18 and a beta of 0.73. Inspire Medical Systems has a fifty-two week low of $38.91 and a fifty-two week high of $147.03. The stock has a fifty day moving average of $49.13 and a 200-day moving average of $73.51.

Inspire Medical Systems (NYSE:INSP) last posted its quarterly earnings results on Monday, May 4th. The company reported $0.10 earnings per share for the quarter, topping the consensus estimate of ($0.28) by $0.38. The company had revenue of $204.58 million during the quarter, compared to the consensus estimate of $200.04 million. Inspire Medical Systems had a return on equity of 10.35% and a net margin of 14.33%.The firm’s quarterly revenue was up 1.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.10 EPS. Inspire Medical Systems has set its FY 2026 guidance at 0.750-1.250 EPS. Equities analysts predict that Inspire Medical Systems will post 0.91 EPS for the current year.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.